Date: 2014-09-03
Type of information: R&D agreement
Compound: new molecules targeting a genetic driver of tumour growth and survival
Company: AstraZeneca (UK) Redx Pharma (UK)
Therapeutic area: Cancer - Oncology
Type agreement: R&D collaboration
Action mechanism:
Disease:
Details: * On September 3, 2014, Redx Pharma announced that it has entered into a research collaboration with AstraZeneca to discover and develop new molecules targeting a genetic driver of tumour growth and survival. The research will complement AstraZeneca\'s strategic approach focused on genetic drivers of cancer and mechanisms of resistance to established and novel cancer therapies. The research collaboration will involve Redx Pharma scientists working with AstraZeneca\'s Oncology Innovative Medicines group to accelerate the drug discovery process. Redx Pharma will use its early stage drug discovery capabilities to identify novel leads whose further development will be supported by AstraZeneca\'s extensive knowledge of the area and strong oncology expertise. Redx Pharma was one of the first tenants at the BioHub at Alderley Park in Cheshire, set up by AstraZeneca in 2013 to allow life sciences companies to benefit from Alderley Park\'s scientific heritage and state-of-the-art research facilities. As part of the collaboration, AstraZeneca and Redx scientists will work together at Alderley Park, as well as at Redx\'s Liverpool facility where the project will be based.
Financial terms: Under the terms of the agreement, Redx Pharma will receive an undisclosed upfront payment. In addition, Redx Pharma is potentially eligible for significant development and commercial milestones, as well as tiered royalties as the programme progresses. AstraZeneca will have the sole rights to further develop and commercialise any programme resulting from the collaboration to add to its portfolio of cancer medicines.
Latest news:
